Prospective associations of androgens and sex hormone-binding globulin with 12-month, lifetime and incident anxiety and depressive disorders in men and women from the general population.
Adult
Aged
Aged, 80 and over
Aging
/ blood
Androgens
/ blood
Androstenedione
/ blood
Anxiety Disorders
/ blood
Depressive Disorder
/ blood
Female
Germany
/ epidemiology
Humans
Longitudinal Studies
Male
Middle Aged
Phobia, Social
/ blood
Prospective Studies
Sex Characteristics
Sex Hormone-Binding Globulin
/ analysis
Testosterone
/ blood
Young Adult
Androgens
Anxiety
Cohort
Depression
Sex hormones
Testosterone
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
received:
22
05
2018
revised:
05
10
2018
accepted:
03
11
2018
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
2
4
2019
Statut:
ppublish
Résumé
Findings on associations of androgens and sex hormone-binding globulin (SHBG) with anxiety and depressive disorders in the general population remain inconclusive. We used data of n = 993 men and n = 980 women from the Study of Health in Pomerania (SHIP, a prospective-longitudinal general population study from northeastern Germany). Immunoassay-measured serum concentrations of total testosterone, androstenedione and SHBG were assessed when participants were aged 20-80. 12-month, lifetime and incident DSM-IV anxiety and depressive disorders were assessed with the DIA-X/M-CIDI at 10-year follow-up, when participants were aged 29-89. Logistic regressions were adjusted for age, smoking, alcohol consumption, physical activity, waist circumference, hypertension and oral contraceptive use (women only) at baseline and follow-up interval. In men and women, androgens and SHBG were not associated significantly with incident anxiety and depressive disorders. In men, higher total testosterone predicted any 12-month (OR = 1.46) and lifetime (OR = 1.34) anxiety disorder, lifetime social phobia (OR = 2.15), and 12-month (OR = 1.48) and lifetime (OR = 1.39) specific phobia, but neither 12-month nor lifetime depression. Moreover, androstenedione in men interacted with age in predicting lifetime anxiety disorders (OR = 0.98): Higher androstenedione more strongly predicted lifetime anxiety in younger vs. older men. These findings, however, did not survive correction for multiple testing. In women, androgens and SHBG were not associated significantly with 12-month and lifetime anxiety and depressive disorders. The follow-up period was relatively long and other factors might have affected the examined associations. Higher serum total testosterone in men and androstenedione in younger men may relate to an increased risk of anxiety disorders.
Sections du résumé
BACKGROUND
Findings on associations of androgens and sex hormone-binding globulin (SHBG) with anxiety and depressive disorders in the general population remain inconclusive.
METHODS
We used data of n = 993 men and n = 980 women from the Study of Health in Pomerania (SHIP, a prospective-longitudinal general population study from northeastern Germany). Immunoassay-measured serum concentrations of total testosterone, androstenedione and SHBG were assessed when participants were aged 20-80. 12-month, lifetime and incident DSM-IV anxiety and depressive disorders were assessed with the DIA-X/M-CIDI at 10-year follow-up, when participants were aged 29-89. Logistic regressions were adjusted for age, smoking, alcohol consumption, physical activity, waist circumference, hypertension and oral contraceptive use (women only) at baseline and follow-up interval.
RESULTS
In men and women, androgens and SHBG were not associated significantly with incident anxiety and depressive disorders. In men, higher total testosterone predicted any 12-month (OR = 1.46) and lifetime (OR = 1.34) anxiety disorder, lifetime social phobia (OR = 2.15), and 12-month (OR = 1.48) and lifetime (OR = 1.39) specific phobia, but neither 12-month nor lifetime depression. Moreover, androstenedione in men interacted with age in predicting lifetime anxiety disorders (OR = 0.98): Higher androstenedione more strongly predicted lifetime anxiety in younger vs. older men. These findings, however, did not survive correction for multiple testing. In women, androgens and SHBG were not associated significantly with 12-month and lifetime anxiety and depressive disorders.
LIMITATIONS
The follow-up period was relatively long and other factors might have affected the examined associations.
CONCLUSIONS
Higher serum total testosterone in men and androstenedione in younger men may relate to an increased risk of anxiety disorders.
Identifiants
pubmed: 30699875
pii: S0165-0327(18)31116-9
doi: 10.1016/j.jad.2018.11.052
pii:
doi:
Substances chimiques
Androgens
0
Sex Hormone-Binding Globulin
0
Testosterone
3XMK78S47O
Androstenedione
409J2J96VR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
905-911Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.